📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Praticien-chercheur
7 articles scientifiques publiés — formation continue solide
Référence presse grand public
Cité 1 fois dans les médias — pédagogie reconnue
Expérience confirmée
36 ans d'exercice en rhumatologie — recul clinique solide
36ans d'exercice (thèse 1990)
✨ Génération du profil synthétique IA en cours…
🎓 DES & spécialité ordinale
🏅 DU / DIU
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
📚 CES (Certificat d'Études Spéciales)
🎓 Diplômes
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
🏆 Diplômes complémentaires reconnus
DIU EA-PR/MAIDIU
Le DIU rhumato généraliste de référence : polyarthrite rhumatoïde, spondyloarthrite, lupus, Sjögren, vascularites. Coordonné par la SFR.
Plusieurs universités, coordination Société Française de Rhumatologie (SFR)
Page d'information générale →Comparaison de la calciurie et de l'hydroxyprolinurie des 24 heures a celles mesurees sur les urines du matin (spot urinaire de 2 heures) chez 124 patients atteints de diverses osteopathies et chez 21 temoins
1990Direction : Pierre Meunier
Clonage et séquençage du génome infectieux d'un Parvovirus d'Insecte, le Densovirus du Lépidoptère Junonia coenia
1990Cloning and sequencing of the infectious genome of an insect parvovirus, the densovirus of junonia coenia (lepidoptera)
Direction : Max Bergoin
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Feasibility of developing classical biological control solutions for the herbaceous weed Allium triquetrum in Australia
2022ArticleBiocontrol Science and Technology
Feasibility of classical biological control of Sonchus oleraceus in Australia
2021ArticleBiocontrol Science and Technology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Source : Google News (recherche par nom complet — homonymes possibles, vérifier le contenu).
📰 Nice-Matin · 17/10/2024
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOTFM0QTVoYk9kR2VoSG9SRWl1QUtYTFhyRzNFN3E3WG51Q0U3ZjhHbDJiOVcxejQ4d2pvTWdoX1YwNlNJTkdvNlUwazR3MXZTbUdnRE9zRUpiRVdmVjZFd1pGOWhEeGRWSUhDVmE4LWY0UG1ZczFJd0hROW1pb3BkR3ZBUDRJdDhLbS1GU05vcWFGUGR4ZzZIM1FiX0dyM0V5eWtSQnhjUUxxdTVGdEJfRlZmRm9MMEdUSl
Clinical cancer research : an official journal of the American Association for Cancer Research · 2015
Abstract Human IL6 is a cytokine produced by many cell types that has pleiotropic effects. In agreement, anti-IL6 therapy reduces inflammation, hepatic acute phase proteins, and anemia and has antiangiogenic effects. Blocking IL6 has demonstrated therapeutic efficacy with drug registration in Castleman disease and inflammatory diseases (rheumatoid arthritis) without major toxicity. Interestingly, the inhibition of C-reactive protein (CRP) production is a trustworthy surrogate marker of anti-IL6 therapy efficacy. Clinically registered IL6 inhibitors include siltuximab, an anti-IL6 mAb, and tocilizumab, an anti-IL6R mAb. In various cancers, in particular plasma cell cancers, large randomized trials showed no efficacy of IL6 inhibitors, despite a full inhibition of CRP production in treated patients in vivo, the numerous data showing an involvement of IL6 in these diseases, and initial short-term treatments demonstrating a dramatic inhibition of cancer cell proliferation in vivo. A likely explanation is the plasticity of cancer cells, with the presence of various subclones, making the outgrowth of cancer subclones possible using growth factors other than IL6. In addition, current therapeutic strategies used in these cancers already target IL6 activity. Thus, anti-IL6 therapeutics are able to neutralize IL6 production in vivo and are safe and useful in inflammatory diseases and Castleman disease. Clin Cancer Res; 21(6); 1248–57. ©2015 AACR.
Arthritis and rheumatism · 1990
AbstractThe constitutive production of interleukin‐6 (IL‐6), a potent hepatocyte‐stimulating factor and B cell‐differentiating factor, was demonstrated in 3 patients with cardiac myxomas. Tumor cells from the only patient who presented with immunologic features produced 14–23‐fold higher levels of IL‐6 than those from the 2 patients who lacked such features. A significant serum IL‐6 level (56 pg/ml), greater than that observed in patients with active rheumatoid arthritis, was also observed only in this patient, with a subsequent return to an undetectable level after surgical removal of the tumor. This was associated with a regression of the immunologic features. This same patient was observed to have an IL‐6‐dependent, proliferative polyclonal plasmacytosis of the bone marrow. These observations demonstrate that an overproduction of IL‐6 by cardiac myxoma cells, in association with a systemic passage of this IL‐6, may be responsible for the immunologic features similar to those observed in true autoimmune diseases such as rheumatoid arthritis.
The Journal of experimental medicine · 1996
We have previously shown that long-term in vitro proliferating fetal liver pre-B cell lines derived from autoimmune-prone (NZB x NZW)F1 (BW) mice, but not normal (B6 x DBA2)F1 mice, can differentiate in severe combined immunodeficient (SCID) mice to produce elevated levels of serum immunoglobulin (Ig) M and IgG, and high titers of antinuclear antibodies The contribution of parental NZB and NZW strains to B cell abnormalities of BW hybrid mice was investigated here by preparing pre-B cells and transferring them into immunodeficient SCID- and RAG-2-targeted mice. We show that transfer of NZB pre-B cells led to a marked IgM hypergammaglobulinemia and to the production of limited amounts of IgG2a. On the other hand, the transfer of NZW pre-B cell lines led to moderately elevated IgM levels and marked hypergammaglobulinemia of IgG2a. High IgM and low IgG anti-DNA titers are found in the recipients of NZB pre-B cells, whereas those receiving NZW pre-B cells contained lower levels of IgM and high titers of IgG anti-DNA. In marked contrast, essentially identical titers of antibodies directed against a non-self-antigen, DNP, are found in all group of pre-B cell recipients. Thus, B-lineage cells of both NZB and NZW parental strains manifest abnormalities associated with the development of this lupus-like disease. Therefore, the present study strongly suggests a complex inheritance of B cell abnormalities in autoimmune-prone (NZB x NZW)F1 mice and emphasizes the critical importance of intrinsic B cell defects in the development of murine systemic lupus erythematosus.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Insects · 2025 · Journal Article
Lesieur V, Thomann T, Jourdan M, Kashefi J, et al.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2015 · Journal Article
Rossi JF, Lu ZY, Jourdan M, Klein B
Arthritis and rheumatism · 1990 · Journal Article
Jourdan M, Bataille R, Seguin J, Zhang XG, et al.
Journal of the Royal Society of Medicine · 1985 · Case Reports
Ridley MG, Price TR, Grahame R, Jourdan M, et al.
Mycological research · 2006 · Journal Article
Gomez DR, Evans KJ, Harvey PR, Baker J, et al.
The Journal of experimental medicine · 1996 · Journal Article
Reininger L, Winkler TH, Kalberer CP, Jourdan M, et al.
Seminars in immunopathology · 2013 · Journal Article
Korkmaz B, Lesner A, Letast S, Mahdi YK, et al.
✨ Profil synthétique
IA · 09/05/2026Le Docteur MIREILLE JOURDAN est un rhumatologue titulaire d'un DIU EA-PR/MAI et d'un doctorat en Médecine, Physiologie, Biologie des organismes et populations ainsi que en Virologie. Ses publications sur PubMed couvrent des sujets tels que la génétique, le lupus et les vascularites. Cette expertise académique et clinique suggère une solide formation et une expérience dans le domaine de la rhumatologie.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.